LEYTON x BIOQUEBEC

On May 30, 2024, from 8:00 am to 11:30 am, we had the pleasure of organizing a joint event with BioQuébec. For the occasion, we welcomed a prestigious discussion panel featuring Benoit Larose, CEO of BioQuébec, Véronique Dugas, Vice-President of CQDM, Claude Leduc, CEO of RNA Technologies and Yvan Côté, CEO of Neopharm.

Laurent Lecanu, Director of Business Development, Pharma Division, was also on hand to lead the discussion on the strategic use of non-dilutive financial levers available in Quebec and Canada to grow and anchor life sciences companies in Quebec.

The questions posed by the audience gave rise to very constructive and fruitful discussions: from concerns about the difficulty of navigating the murky waters of funding opportunities, to the absence of a program that would fund 100% of a given project, to the evolution of the SR&ED program.

Concluding remarks underlined the need for biotech/pharmaceutical/medical companies to make IP strategy and use the SR&ED Tax Credit Program a top priority. And despite the obstacles identified, the multiplicity and depth of funding programs, Quebec is both a unique and attractive location.

To illustrate this, Laurent Lecanu posed the following question: “I know the answer, but I have to ask if there’s reason to be optimistic about the life sciences industry in Quebec”.

The panelists unanimously answered “Yes”. Like them, he shares this opinion: “Quebec has all the resources – human, scientific, manufacturing and logistical – to become a major player in innovation and a key partner in the international life sciences sector. If you are developing an R&D project in the life sciences sector, contact our experts to find out which programs are eligible for your company.“

Don’t wait to join our next Leyton events! Subscribe to our newsletter to receive our exclusive news.